Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11122506 | 1.00 | AKT1 (0.39) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL497015 | 1.00 | AKT1 (0.39) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL11124429 | 1.00 | AKT1 (0.39) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL11126408 | 1.00 | AKT1 (0.39) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL496837 | 0.94 | AKT1 (0.41) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL29396090 | 0.88 | AKT1 (0.51) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL11084352 | 0.81 | S1PR4 (0.36) | — | |
| SCHEMBL11289177 | 0.81 | S1PR4 (0.36) | — | |
| SCHEMBL11090273 | 0.81 | S1PR4 (0.36) | — | |
| SCHEMBL11084350 | 0.81 | S1PR4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | claimed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | claimed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | claimed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | claimed |
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | disclosed |
| EP-0781138-B1 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | UNIV WAKE FOREST (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7294621-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294620-B2 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294619-B2 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1852121-A2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-7141557-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-28 | — | — | US | disclosed |
| US-7135584-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7129227-B1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080050-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040259845-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| US-5962437-A | HEPATITIS, HERPES AND AIDA VIRUS | WAKE FOREST UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | SGMS1, HDLBP, LIPC | AKT1 1239/4885LMNA 2728/4885ESR1 4384/4885 |
| US-20040259845-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | AKT1 1836/4885LMNA 3758/4885ESR1 4108/4885 |
| US-20050080050-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | AKT1 1836/4885LMNA 3758/4885ESR1 4108/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | AKT1 1553/4885LMNA 2362/4885ESR1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.